Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NeoImmuneTech, Inc.
Also, Neoimmune looks to interleukin therapy for mild therapy while Daiichi Sankyo bets on a mRNA vaccine.
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
After using government financial support to fund its early-stage clinical trials, Korean bioventure Cellid aims to further progress its first-in-class, cell-based cancer immunotherapeutic vaccines through an initial public offering in February.
Daiichi Sankyo gains worldwide rights to an antibody-drug conjugate version of Glycotope’s gatipotuzumab for various cancers. Also, Tasly buys China rights to Mesoblast's CV candidates and India's Cipla grows in Africa.
- Gene Therapy, Cell Therapy
- Large Molecule